Johnson & Johnson (NYSE: JNJ) remains one of the most reliable dividend-paying companies in the stock market. With a market value of nearly $425 billion, the pharmaceutical and medical device giant continues to deliver growth while rewarding shareholders. Its 63-year record of increasing dividends sets it apart as one of the most dependable blue-chip stocks for income investors.
In the second quarter of 2025, Johnson & Johnson reported revenue growth of 5.8% compared to the same period last year. Earnings also climbed by 18%, reflecting the company’s ability to expand even in a competitive healthcare landscape. Investors benefit not only from strong fundamentals but also from steady cash returns. As of September 19, JNJ pays a quarterly dividend of $1.30 per share, offering a yield of 2.95% (Yahoo Finance – JNJ stock)
Strong Pharmaceutical Portfolio
Johnson & Johnson has built a robust portfolio across immunology, oncology, and medical devices. Its key drugs include Stelara and Tremfya in immunology, along with cancer treatments like Darzalex and Erleada. The company currently has 40 late-stage clinical trials underway, which could further expand its drug pipeline and strengthen future revenue streams (CNBC Healthcare Coverage).
Until 2023, JNJ also operated a consumer healthcare division responsible for iconic products such as Tylenol and Band-Aid. That business was spun off into Kenvue, allowing Johnson & Johnson to sharpen its focus on pharmaceuticals and medical technology. You can read more about spinoffs and market shifts in our dividend investing guide.
Why Investors Value JNJ’s Dividend
A 63-year track record of dividend growth makes Johnson & Johnson especially attractive to long-term investors. Few companies have such consistency, and JNJ’s strong balance sheet supports ongoing increases. For income-focused investors, this reliability sets JNJ apart from many peers (Investopedia – Dividend Investing).
While Johnson & Johnson remains a cornerstone of dividend-paying stocks, analysts note that high-growth sectors such as artificial intelligence may offer greater upside. Still, for those seeking stability and proven performance, JNJ continues to be one of the most trusted names in the market. To explore other opportunities, check out our article on Nvidia OpenAI investment.
